Please ensure Javascript is enabled for purposes of website accessibility

Welcome to Regulatory Rapporteur. This site uses cookies. Read our policy.

  • Skip to main content
  • Skip to navigation
Site name
topra-logo

The Organisation for Professionals in Regulatory Affairs
Site name
Mast navigation
  • Become a member
  • Sign in
Search our site
Menu
Close menu
  • Regulatory Rapporteur - July/August 2026
  • Pharmaceuticals
    • Back to parent navigation item
    • Pharmaceuticals
    • Artificial intelligence
    • ATMP
    • Biologics
    • Chemistry, manufacturing and controls
    • Clinical trials
    • Non-clinical development
    • Oncology
    • Product information
    • Regulatory procedures
  • Veterinary
  • Medical devices
    • Back to parent navigation item
    • Medical devices
    • Combination products
    • In-vitro diagnostics
    • Software
    • Artificial intelligence
  • Industry news
    • Back to parent navigation item
    • Industry news
    • Industry news
      • Back to parent navigation item
      • Industry news
      • Read latest news
      • Video
  • Commentary
    • Back to parent navigation item
    • Commentary
    • Editorials
    • Podcasts
    • Thought leadership
    • Letters to the Editor
  • Collections
    • Back to parent navigation item
    • Collections
    • Interviews
    • Symposium 2025
    • Symposium 2024
    • Symposium 2023
    • Symposium 2022
    • Symposium 2021
    • Regulatory Careers Live
    • CPD supplements
      • Back to parent navigation item
      • CPD supplements
      • 2021/2022
      • 2020
      • 2019
  • JOIN TOPRA
  • topra-logo

    The Organisation for Professionals in Regulatory Affairs
  • Regulatory Rapporteur - July/August 2026
  • Pharmaceuticals
      • Artificial intelligence
      • ATMP
      • Biologics
      • Chemistry, manufacturing and controls
      • Clinical trials
      • Non-clinical development
      • Oncology
      • Product information
      • Regulatory procedures
    • AdobeStock_2031070488_main image
      Drug development and regulatory pathways across therapeutic areas
    • AdobeStock_230080191_main image
      Navigating the regulatory landscape of adverse events following immunisation: Current challenges and future perspectives
    • AdobeStock_1057710391_main image
      The development of novel influenza drugs: Current regulatory challenges
  • Veterinary
    • VET main image
      A career in veterinary regulatory affairs: Roles and competencies across the product lifecycle
    • Jana Schalansky
      November 2025 – Contents: Veterinary medicines sessions
    • RR-June-2025-half cover _masthead
      June 2025 – Contents
    • June cover image licensed
      Veterinary medicines: Translating regulation into practice
  • Medical devices
      • Combination products
      • In-vitro diagnostics
      • Software
      • Artificial intelligence
    • 1. image 1 same image in previous MedDev updates
      Medical device standards update: July 2026
    • AdobeStock_1357495965
      Medical Device Regulation 2.0: Why stakeholder disagreement is bad for all
    • GATEKEEPER main image
      From gatekeepers to collaborators: Regulatory evolution toward risk-based lifecycle approaches in an era of innovation
  • Industry news
      • Industry news
        • Read latest news
        • Video
    • AdobeStock_1761195483
      FDA finalises guidance aimed at widening access to cancer clinical trials
    • AdobeStock_2108880983
      New diabetes treatment and a Vetmedin referral: Inside the CVMP July 2026 meeting
    • AdobeStock_393573411
      CHMP July meeting brings first-of-its-kind eye implant and oral psoriasis breakthrough
  • Commentary
      • Editorials
      • Podcasts
      • Thought leadership
      • Letters to the Editor
    • TOPRA RR Future-Proof Regulatory Affairs 800x533px (6.4 ratio)
      RegRapPod − InConversation with Aman Khera
    • cover image
      Therapeutics: Navigating diverse regulatory pathways
    • Main image
      Lifecycle management: Enhancing regulatory agility
  • Collections
      • Interviews
      • Symposium 2025
      • Symposium 2024
      • Symposium 2023
      • Symposium 2022
      • Symposium 2021
      • Regulatory Careers Live
      • CPD supplements
        • 2021/2022
        • 2020
        • 2019
    • Banner_new
      Streamline medical device compliance with BSI Compliance NavigatorSponsored by The UK's National Standards Body
    • AdobeStock_59790119
      The Olaratumab experience
    • AdobeStock_207448226
      Qualification of stride velocity endpoint in Duchenne Muscular Dystrophy
  • JOIN TOPRA
  • More from navigation items

Pharmaceutical latest

  • AdobeStock_1761195483

    FDA finalises guidance aimed at widening access to cancer clinical trials

    2026-08-12T11:44:00+01:00

  • AdobeStock_393573411

    CHMP July meeting brings first-of-its-kind eye implant and oral psoriasis breakthrough

    2026-08-06T15:03:00+01:00

  • AdobeStock_708769458

    FDA launches new guidance on development of psychedelic drugs to treat medical conditions

    2026-07-31T08:49:00+01:00

  • AdobeStock_1959640627

    USP 2025 Annual Drug Shortages Report: Shortages decline but duration increases

    2026-07-21T09:57:00+01:00

  • AdobeStock_93980790

    EU roadmap sets out 22 actions to phase out animal testing in chemical safety assessment

    2026-07-21T08:05:00+01:00

  • AdobeStock_572256673

    New MHRA framework sets out IMA pathway for rare disease therapies

    2026-07-17T15:17:00+01:00



  • AdobeStock_2070282556

    FAST-EU pilot delivers first results: 70-Day approval timelines prove feasible ahead of Biotech Act

    2026-07-09T15:15:00+01:00

  • AdobeStock_480282897

    European Commission publishes first joint clinical assessment under EU HTA regulation

    2026-07-09T09:45:00+01:00

  • AdobeStock_911354716

    FDA launches Operation TrialBlazer to accelerate US clinical research

    2026-07-09T09:15:00+01:00

  • Environmental impact of pharmaceuticals and regulation in the EU

    Environmental impact of pharmaceuticals and regulation in the EU

    2026-07-03T17:05:00+01:00

  • Half cover_final

    Regulatory Rapporteur July/August 2026 – Contents

    2026-07-02T16:57:00+01:00

  • AdobeStock_2031070488_main image

    Drug development and regulatory pathways across therapeutic areas

    2026-07-01T14:45:00+01:00

  • AdobeStock_230080191_main image

    Navigating the regulatory landscape of adverse events following immunisation: Current challenges and future perspectives

    2026-06-30T15:16:00+01:00

  • AdobeStock_1057710391_main image

    The development of novel influenza drugs: Current regulatory challenges

    2026-06-30T14:55:00+01:00

  • AdobeStock_487121091_main image

    Advancing fertility therapeutics: Scientific, clinical and regulatory challenges in assisted reproduction

    2026-06-30T14:20:00+01:00

  • AdobeStock_1984419336_main image

    Environmental risk assessment of human medicinal products in the EU: Legacy APIs, data reuse, and the governance bottleneck after the 2024 guideline revision

    2026-06-30T13:04:00+01:00

  • National Commission

    The National Commission into the Regulation of AI in Healthcare releases survey findings

    2026-06-16T15:12:00+01:00

  • SAFETY- main image

    Enhancing post-market surveillance with Artificial Intelligence and predictive analytics

    2026-06-09T08:30:00+01:00

More pharmaceutical content

  • What is Regulatory Affairs?
  • TOPRA Membership
  • Regulatory Rapporteur Editorial Board
  • Regulatory Rapporteur Editorial Area
  • Future Focus Topics
  • FAQs
  • Glossary
  • Privacy Policy
  • ISSN 2755-5070 (online)

    ISSN 1742-8955 (print - legacy)

Regulatory Rapporteur

The peer-reviewed journal, published 11 times per year and available free to TOPRA members.

Follow TOPRA
topra-logo

The Organisation for Professionals in Regulatory Affairs

TOPRA office
TOPRA Publishing, Third floor, City Reach, 5 Greenwich View Place, London E14 9NN, UK
Tel: +44 (0) 20 7510 2560
Email: publications@topra.org

TOPRA AISBL
Blvd du Souverain 280, 1160 Brussels, Belgium
Tel: +32 (0) 2 808 72 70

  • Contact us
  • Copyright © 2015-2026 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved

Site powered by Webvision Cloud